Desmopressin

DDAVP, dDAVP, 1-deamino-8-D-arginine vasopressin, desmopressin acetate; Minirin, Nocdurna, Noctiva, Stimate, Octostim, DesmoMelt

Sexual health, hormones & signalling

Awaiting medical reviewEN ES DE FR PT ZH+ Follow for updates

Note on this profile. Desmopressin is an approved prescription medicine in most countries, not a research-only compound. This page explains the published science. Use outside a prescription, including the "water manipulation" and nasal "nootropic" uses discussed online, carries a real and well-documented risk of dangerous low sodium.

Summary

Class: Synthetic analogue of the natural hormone vasopressin (a 9-amino-acid cyclic peptide), modified at two positions to remove blood-pressure activity and prolong action
Mechanism: Selectively activates vasopressin V2 receptors: in the kidney this concentrates urine and retains water; in blood vessels it releases stored von Willebrand factor and factor VIII
Routes studied: Intranasal spray, oral tablet, sublingual melt, intravenous and subcutaneous injection
Dose range reported: Approved: central diabetes insipidus — intranasal 10–40 µg/day, oral 0.1–1.2 mg/day in divided doses, injection 2–4 µg/day; nocturnal enuresis — oral 0.2–0.6 mg at bedtime (melt 120–240 µg); nocturia from nocturnal polyuria — sublingual 25 µg (women) / 50 µg (men) at bedtime (Nocdurna); bleeding disorders — 0.3 µg/kg IV/SC, or 150 µg per nostril of the 1.5 mg/mL spray. Research (memory): 20–60 µg intranasal. Community: unspecified nasal or oral doses for water loss or cognition
Half-life: Roughly 1.5–3.5 h depending on route (oral shortest, intranasal longest); antidiuretic effect lasts 8–12 h or more
Storage: Nasal sprays and injection: refrigerate (some sprays room temperature once opened, per label); tablets and melts: room temperature, dry
Regulatory status: Approved medicine (US, EU, UK, AU, ZA and many others)

Doses are as reported in studies or by the community — never recommendations.

1What it is

Desmopressin is a slightly altered copy of vasopressin, the pituitary hormone that tells the kidneys to hold on to water. Two changes — removing an amino group at position 1 and swapping L- for D-arginine at position 8 — strip away vasopressin's blood-vessel-constricting (V1) effect and make the molecule last far longer. It was synthesised in Czechoslovakia in 1967 and has been in use since the 1970s for diabetes insipidus, bedwetting, nocturia and, at higher doses, to stop bleeding in mild haemophilia A and von Willebrand disease. It is on the WHO essential medicines list.

2How it's thought to work

Kidney (V2). V2 activation in the collecting ducts moves aquaporin-2 water channels into the cell membrane, so water is reabsorbed and urine becomes concentrated. Urine output falls for 8–12 hours after a dose.

Haemostasis (V2 on endothelium). triggers release of von Willebrand factor and factor VIII from Weibel–Palade bodies, raising their blood levels 2–4-fold within an hour. Stores are depleted by repeated daily doses (tachyphylaxis after 2–3 doses).

Brain. vasopressin receptors in the brain are implicated in memory and social behaviour; whether intranasal desmopressin reaches them in meaningful amounts is unresolved.

No pressor effect. at therapeutic doses, unlike vasopressin itself.

Vasopressin modified to keep the kidney effect and drop the blood-pressure one. Only the water-retaining arm of the figure applies, which is why it is used for diabetes insipidus and bedwetting.Schematic — not to scale

3What the research shows

Graded A/B

Central diabetes insipidus

The reference treatment since the 1970s; controls polyuria in nearly all patients with intact kidneys. Evidence is largely from older uncontrolled series and decades of practice rather than large .

Nocturnal enuresis in children

Reduces wet nights by about 1.3 per week versus placebo and roughly doubles the chance of 14 consecutive dry nights, but relapse after stopping is common (Glazener & Evans 2002, Cochrane). Alarm therapy has better long-term results. [3]

Nocturia due to nocturnal polyuria

Oral desmopressin reduced nocturnal voids and increased the first uninterrupted sleep period in RCTs in men (Mattiasson 2002, BJU Int) and women (Lose 2003, Am J Obstet Gynecol). Low-dose sublingual formulations were developed after sex-specific dose-finding showed women respond to lower doses (Sand 2013 and Weiss 2013, J Urol). Approved US products carry a boxed warning for hyponatraemia. [4][5][6]

Graded A/B

Mild haemophilia A and type 1 von Willebrand disease

Raises factor VIII and vWF enough to cover minor surgery and bleeds in responsive patients (Mannucci 1977, Lancet; Mannucci 1997, Blood review). A test dose is standard, because response varies by subtype. [1][2]

Memory and cognition

Small 1980s studies reported improved recall after intranasal desmopressin in healthy volunteers and some patient groups (Weingartner 1981, Science), but results were inconsistent, effects modest, and the line of research was largely abandoned. No modern well-powered trial supports cognitive use. [8]

Bodybuilding "water manipulation"

Community reports describe nasal or oral desmopressin to retain or shed water before contests. No studies; several published case reports of severe hyponatraemia in this context.

4Reported side effects and interactions

Literature-reported

Common (literature). headache, nausea, facial flushing, abdominal cramps, nasal congestion or irritation (spray), mild rise in blood pressure (rare).

Serious / warnings. hyponatraemia, which can cause confusion, seizures, coma and death; risk rises with fluid intake, age (>65), low body weight, higher doses, intranasal route and co-medication (Rembratt 2006, Neurourol Urodyn). Boxed warning on US nocturia products. Fluid restriction from 1 hour before to 8 hours after a dose is standard advice. Contraindicated in hyponatraemia, moderate-to-severe renal impairment (CrCl <50 mL/min), SIADH, heart failure or other conditions requiring diuretics, uncontrolled hypertension (nocturia products), and polydipsia. Rare thrombotic events with high haemostatic doses. The US nasal spray lost its enuresis indication in 2007 after hyponatraemic seizures in children.

Community-reported

headache, nausea, water retention and puffiness, "flat" appearance from over-correction, and in several cases hospitalisation for low sodium.

Interactions. drugs that raise hyponatraemia risk — SSRIs, tricyclics, carbamazepine, oxcarbazepine, lamotrigine, chlorpromazine, NSAIDs, opioids, thiazides. Loop diuretics and systemic glucocorticoids are contraindicated with low-dose nocturia products. Alcohol and large fluid intake defeat the purpose and raise the risk.

Markers researchers commonly monitor

Per label and clinical practice:

Marker	Why it's watched
Serum sodium	the critical safety marker; baseline, within the first week, after any dose increase, and periodically (more often over 65).
Serum and urine osmolality	confirm antidiuretic effect and diagnosis in DI.
Body weight and fluid intake/output diary	rapid weight gain signals water retention before sodium falls.
eGFR/creatinine	renal impairment is a contraindication.
Blood pressure	occasional small rises; also relevant to the nocturia-product contraindication.
Factor VIII and von Willebrand factor levels	before and 1 hour after a test dose in bleeding disorders.
Frequency-volume chart	the outcome measure in nocturia and enuresis.

Free for everyone. Safety information is never behind a paywall.

5Reconstitution and handling

All approved presentations are ready to use; no . Dosing confusion between micrograms and milligrams (tablets are in mg, sprays in µg per spray, injection in µg/mL) is the main source of error. The calculator is not applicable to approved dose forms. (for µg/mg conversions only)

Open in calculator, pre-loaded →

6Commonly studied alongside

Vasopressin (parent hormone, this batch), oxytocin (structurally related neuropeptide, intranasal research), tranexamic acid (combined for bleeding control, not a peptide), anticholinergics and alarm therapy (enuresis comparators).

Informational cross-links. Not stack recommendations.

7Regulatory status by region

Region	Status (checked —)
United States	FDA-approved: DDAVP tablets, nasal spray and injection (DI, haemophilia A/vWD; tablets also enuresis); Nocdurna and Noctiva (nocturia, boxed warning). Stimate spray subject to recall/shortage since 2020 †
European Union	Authorised nationally (Minirin, Nocdurna, Octostim, DesmoMelt and generics)
United Kingdom	MHRA-licensed; prescription-only
Australia	TGA-approved (Minirin, Nocdurna); S4
South Africa	SAHPRA-registered (Minirin, Octostim); prescription-only
Sport	Prohibited by WADA under S5 (diuretics and masking agents)

8Open questions

Whether intranasal desmopressin reaches the brain in meaningful quantity; the cognitive literature never settled this.
Optimal duration and tapering in enuresis to reduce relapse.
Safe use in older adults, where the hyponatraemia risk–benefit remains debated.

9References

1Mannucci PM et al. (1977). 1-Deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand's disease. Lancet. PubMed · DOI
2Mannucci PM (1997). Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood. PubMed
3Glazener CM, Evans JH (2002). Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev. PubMed · DOI
4Mattiasson A et al. (2002). Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int. PubMed · DOI
5Lose G et al. (2003). Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am J Obstet Gynecol. PubMed · DOI
6Weiss JP et al. (2013). Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol. PubMed · DOI
7Rembratt A et al. (2006). Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol Urodyn. PubMed · DOI
8Weingartner H et al. (1981). Effects of vasopressin on human memory functions. Science. PubMed · DOI
9DDAVP / Nocdurna / Minirin prescribing information and SmPC (current). PubMed

References are being resolved to PubMed/DOI identifiers; links search PubMed for the citation until then.

† Being confirmed by our reviewers against current sources.

10Community

forum threads →

community protocols include this →

Threads and protocols are visible to members. Joining is free.

Self-reported side effects Phase 2

Not enough data yet. 0 of the 50 members needed have logged this compound for 4+ weeks. We don't show anything below 50, so no one can be identified.

11Page history

26 Oct 2026Profile published — awaiting medical review

Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.